← Back to Clinical Trials
Recruiting NCT06541626

NCT06541626 Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06541626
Status Recruiting
Phase
Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition Multiple Sclerosis, MS
Study Type OBSERVATIONAL
Enrollment 450 participants
Start Date 2024-01-01
Primary Completion 2035-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 450 participants in total. It began in 2024-01-01 with a primary completion date of 2035-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions. The main questions it aims to answer are: Question 1: Clarify the clinical characteristics and prognostic factors of various diseases (MS, NMOSD, MOGAD, etc.) within IIDD in the Chinese population. Question 2: Analyze the relationship between biomarkers and the occurrence, progression, and prognosis of CNS IIDD cases in our hospital. Participants will 1. Receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions. 2. Receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.

Eligibility Criteria

Inclusion Criteria: 1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD); 2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E); 3. Agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. History of tumors or diagnosis of central nervous system tumors; 2. Infectious lesions of the central nervous system; 3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain/spinal cord; 4. Non-compliance with treatment and follow-up.

Contact & Investigator

Central Contact

Hongxuan Wang

✉ wanghx8@mail.sysu.edu.cn

📞 86+13824498978

Frequently Asked Questions

Who can join the NCT06541626 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis, MS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06541626 currently recruiting?

Yes, NCT06541626 is actively recruiting participants. Contact the research team at wanghx8@mail.sysu.edu.cn for enrollment information.

Where is the NCT06541626 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06541626 clinical trial?

NCT06541626 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The trial plans to enroll 450 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology